Kornimate/medical-research-clean huggingface dataset:
studying biomarkers in cell samples from young patients with acute myeloid leukemia

Conditions: Leukemia

Summary: rationale: studying samples of tissue from patients with cancer in the laboratory may help doctors learn more about changes that occur in dna and identify biomarkers related to cancer. it may also help doctors predict how well patients will respond to treatment. purpose: this research study is looking at biomarkers in cell samples from young patients with acute myeloid leukemia.

objectives: * to characterize stat3 signaling pathway activity in primary tissue samples from pediatric patients with acute myeloid leukemia to determine the percentage of samples with increased activity and to better understand the mechanisms leading to increased activity. * to evaluate the presence of constitutive stat3 activation and the sensitivity of stat3 activation to low and high doses of cytokines. * to evaluate the expression levels of stat3 protein as well as upstream and downstream regulators of stat3 activation. * to classify tissue samples according to a stat3-activation pattern, and to correlate this result with event-free survival and overall survival in order to determine whether increased stat3 phosphorylation at diagnosis predicts poor outcome. outline: cryopreserved cell samples are collected for laboratory analysis, including immunoblotting, fluorescence activated cell sorting (facs), and protein analysis.

Eligibility criteria:
disease characteristics: * diagnosis of pediatric acute myeloid leukemia patient characteristics: * not specified prior concurrent therapy: * not specified

Keywords: childhood acute myeloid leukemia/other myeloid malignancies
a study to assess the effectiveness and safety of different doses of asp1707 compared to placebo for endometriosis associated pelvic pain

Conditions: Endometriosis

Summary: the main objective for this study is to assess the efficacy and dose-response relationship of asp1707 in reduction of endometriosis associated pelvic pain. the secondary objectives are to assess the safety, tolerability, pharmacokinetics of asp1707, dose response relationship of asp1707 in reduction of e2 (estradiol), 24-week efficacy of asp1707 in reduction of endometriosis associated pain and 24-week safety and tolerability of asp1707.


Eligibility criteria:
inclusion criteria: * pre menopausal female adults with confirmed length and regular menstrual cycle * surgically diagnosed endometriosis * moderate to severe endometriosis related pain exclusion criteria: * hormonal contraceptives or other drugs with effects on gynecological endocrinology * surgery for endometriosis within the 4 weeks prior to entry * uterine myoma * abnormal vaginal bleeding * hysterectomy or bilateral oophorectomy * pelvic infection * relevant abnormalities at gynecological exam at screening * disease with chronic abdominal pain of non-endometriosis origin * pituitary adenoma

Keywords: phase 2 double-blind pelvic pain asp1707 placebo-controlled endometriosis
the target-eft randomized clinical trial

Conditions: Frailty; Cardiovascular Diseases in Old Age; Geriatric Cardiology; Quality of Life

Summary: randomized clinical trial to determine whether a multicomponent intervention will lead to improvements in mobility, self-care, mood, pain, and physical activity among frail and pre-frail older adults (as measured with the essential frailty toolset; eft) hospitalized for an acute cardiovascular illness.

the investigators will conduct a single-center randomized clinical trial at the jewish general hospital; an academic tertiary care center in montreal, quebec. researchers will pre-screen stable patients ≥65 years of age admitted to the cardiovascular unit. the investigators will target those that consent and have evidence of frailty or pre-frailty according to the eft (score ≥1/5). the eft consists of a chair rise test to screen for physical frailty, a mini-cog test to screen for cognitive impairment, a hemoglobin level and a serum albumin level. patients will be randomly allocated to the usual-care control group, or the intervention group that will receive targeted treatments depending on the eft deficits identified. all patients will be outfitted with a hip-worn accelerometer to monitor position, step count, and sleep data during the study period. patients will undergo a structured questionnaire and physical performance assessment at baseline (upon index admission) and at discharge, and will be contacted by telephone 30 days post-discharge to assess their recovery. the primary endpoint will be represented by the eq-5d scale (mobility, self-care, mood, pain, and physical activity) measured by blinded observers.

Eligibility criteria:
inclusion criteria: * age ≥65 years * frail or pre-frail as defined by eft score ≥1 * admission to the jgh cardiovascular unit * signed informed consent exclusion criteria: * expected discharge within \<3 days * clinically unstable (unstable vital signs, low-threshold coronary ischemia, uncontrolled heart failure, uncontrolled arrhythmia) * awaiting cardiac surgery during the index hospitalization * severe dementia (mmse ≤10/30) * delirium (cam positive) * psychiatric condition precluding cooperation * not english or french speaking * parkinson's disease * recent stroke \<7 days * bed-bound or paraplegic * end-of-life care plan

Keywords: randomized clinical trial frailty intervention
use of human papillomavirus persistence for determination of treatment efficacy among women with cervical dysplasia

Conditions: Human Papillomavirus Infection; Cervical Intraepithelial Neoplasia

Summary: the objectives are to evaluate the effectiveness of treatment of cervical intraepithelial neoplasia (cin) by loop electrosurgical excision procedure using persistence of human papillomavirus (hpv) as outcome, and to perform a long-term follow-up on the ability of hpv testing, as compared to cytology, to predict recurrence of high-grade cin.

cervical samples for human papillomavirus (hpv) dna analysis and cytological analysis were obtained from women with abnormal smears referred to umeå university hospital, sweden, for treatment with conization. these women were scheduled for hpv dna testing and pap smears before and 3, 6, 12, 24 and 36 months after treatment. the hpv dna testing was performed with a pcr-based genotyping method.

Eligibility criteria:
inclusion criteria: * referral to umeå university hospital for treatment due to abnormal pap smear. exclusion criteria: * lack of informed consent.
alcohol challenge on liver and gut measured by liver vein catheterization. a pathophysiological intervention trial

Conditions: Liver Fibroses; Alcohol-Induced Disorders

Summary: to investigate the effects of acute alcohol challenge on the gut and liver axis.

to study the role of acute alcohol challenge on the intestine permeability and inflow of bacterial products to the liver in participants with alcoholic liver disease, non-alcoholic steatohepatitis and healthy controls.

Eligibility criteria:
inclusion criteria: * alcoholic liver fibrosis, non-alcoholic steatohepatitis or liver-healthy individuals and all of following: * bodymass \> 50 kg * able to be fasting and abstinent on the day of intervention * international ratio \ 100 x 10\^9, 7 days before the intervention day * informed consent exclusion criteria: * antibiotics during the last 4 weeks * total alcohol abstinence * desire of total alcohol abstinence * other causes of liver disease suspected (viral, autoimmune, haemochromatosis, wilsons diseases, alfa 1 antitrypsin deficiency or drug induced) * cirrhosis * insulin dependent diabetes mellitus * incapable to follow the protocol instructions * pregnancy * primary or secondary liver cancer * severe comorbidity * allergic to the contrast media iohexol
a real-world assessment of a copd disease management support service (me & my copd)

Conditions: Chronic Obstructive Pulmonary Disease

Summary: a real world study to determine the effectiveness of a patient support service to aid copd patients in their self management.

the purpose of the study is to evaluate a digital health wellness support tool for patients in primary care with copd using a smart mobile app, patient web portal and technology attached to the patients saba reliever inhaler. using the patients pre-defined copd self management plan, the active arm of the study complete a daily diary (exact pro) and record their daily saba inhaler usage. after defining a health and symptom score baseline over a two week period, any significant deviations in saba reliever use or daily diary scoring will alert patients that they may be having a change in their symptoms and advise them to refer to their self management plan and if they need to start their rescue medication. the primary outcome measure for the study is a 25% reduction in unplanned copd hospital admissions (n=250 completing the study in each arm).

Eligibility criteria:
inclusion criteria: * clinical diagnosis of copd * fev1/fvc ratio \>0.3-\ 30% post-bronchodilator * prescribed either ics, laba and or lama at dose for copd * exacerbations reported within the last 12 months requiring treatment with \>1 systemic steroid and/or antibiotics, or hospitalisation within last 12 months due to exacerbation, or have received \>12 saba prescriptions in previous 12 months * patient has a self management plan which includes use of an oral steroid at a dose within nice guidelines, and additionally antibiotics as appropriate. exclusion criteria: * symptomatic asthma or seasonal allergic rhinitis leading to hospitalisation in previous 12 months * patients unable to use a mobile phone

Keywords: copd, exacerbation, respiratory disease, lung disease, breathlessness, dyspnoea, sputum, wheezing, cough
the tobramycin study

Conditions: Neutropenia; Fever; Cancer

Summary: evaluate if tobramycin given once a day is at least as efficacious as the traditional tobramycin given three times a day, given with penicillin g, til patients with febrile neutropenia.

prospective randomized norwegian multicenter clinical trial (11 hospitals) comparing tobramycin given once a day (new regimen) vs. three times a day (current regimen), with penicillin g, to cancer patients with febrile neutropenia. tobramycin half life and postantibiotic effect is at best 12 hours. it has been questioned if tobramycin once a day is safe in patients with low levels of granulocytes when it is given with a drug like penicillin g which is not covering gram-negative rods. treatment of febrile neutropenia with penicillin g and an aminoglycoside is standard of care in norway, and it is probably a regimen that is promoting antimicrobial resistance less than a broad spectrum beta-lactam. cancer patients 16-70 with febrile neutropenia and signed informed consent could be randomized. exclusion criteria were allergy to study medications, increased creatinine/renal failure, massive ascites, multiple myeloma, treatment with cis-platinum, recent therapy with aminoglycoside (4 weeks) or other antibiotics (4 days), hemodynamically unstable patients, pregnant and nursing patients. patients were stratified into three groups: leukemia patients receiving intensive chemotherapy, lymphoma patients receiving high dose chemotherapy with autologous stem-cell support and other cancer patients. patients were randomized to either tobramycin once or three times a day. once the patient was randomized and the first antibiotic dose was given, further antibiotic therapy was up to the patient's doctor's discretion (not blinded). everybody received tobramycin 6 mg/kg/day and penicillin 5 mill. ie four times a day. the patients were followed until all antibiotic therapy was terminated. clinical condition and laboratory test results at time of randomization (new fever) was registered. response to therapy, reason for modification of therapy, mortality, duration of neutropenia, maximum creatinine level, tobramycin serum concentrations, microbiological findings and total antibiotic consumption were registered. after external monitoring of all the data the results are currently being made up and will be available for publication in 2006. this trial has been conducted independently of the pharmaceutical industry. grants have been received from the norwegian radium hospital research fund, the regional health authorities and the norwegian society for infectious diseases.

Eligibility criteria:
febrile neutropenia cancer adult (16-70) signed informed consent

Keywords: fever neutropenia tobramycin aminoglycoside penicillin
pioglitazone vs. placebo in association with pegylated interferon and ribavirin in hcv patients with insulin resistance

Conditions: Chronic Hepatitis C; Insulin Resistance

Summary: the purpose of this study is to test whether the correction of insulin resistance with pioglitazone, will improve the response to antiviral treatment.

in patients infected with genotypes 1, 4, 5 and 6, the response rate to antiviral therapy remains suboptimal (less than one in two patients have a sustained virological response), which justifies the search for strategies optimizing the results of antiviral therapy. some factors associated with non response have been identified. among the modifiable factors, numerous series have shown that insulin resistance adversely impacts the rate of sustained virological response. the aim of this study is to determine whether the pharmacological correction of insulin resistance through therapy with glitazones restores higher rates of viral eradication and to determine the impact on the kinetics of viral response. patients will be randomized to receive pioglitazone or placebo starting 4 months before initiating pegylated interferon and ribavirin and continued throughout the whole antiviral treatment period.

Eligibility criteria:
inclusion criteria: * 18 years old or older * chronic hcv infection documented by pcr with genotype hcv-1, 4, 5 or 6 * naive patient(never treated with antivirals for hcv) * homa score higher than 2.5 * patient for which the investigator decided to start antiviral treatment for chronic hepatitis c exclusion criteria: * cardiovascular disease: heart failure stage nyha ii, iii or iv, unstable angina, myocardial infarction in the previous year, cardiac surgery or stroke * alcohol consumption exceeding 40 g / day * decompensated liver disease: child-pugh b 8 or higher, or one of the following : bilirubin over 35 mol / l, tp below 50%, ascites, encephalopathy * hepatocellular carcinoma or any other neoplasm (except if in remission for \> 5 years) * other documented chronic liver disease * insulin treated diabetes * hbv or hiv co-infection infection confirmed * thrombocytopenia below 50 000/mm ³; neutropenia below 750/mm ³ or hemoglobin below 11 g / dl * drug-induced steatosis(tamoxifen, glucocorticosteroids, amiodarone, tetracyclines). * bone marrow or solid organ transplantation * pregnancy or breastfeeding, or desire for pregnancy during the study period. * patients under legal protection or unable to express their consent

Keywords: hepatitis c; insulin resistance; glitazones; pioglitazone; steatosis; viral kinetics; antiviral response
patellar resurfacing in total knee arthroplasty leads to better isokinetic performance and higher clinical scores

Conditions: Knee Osteoarthritis

Summary: for decades there have been concerns about patellar resurfacing (pr) in total knee arthroplasty (tka) and the individual preference of the surgeon is still the main determinant of whether or not resurfacing is applied. according to preference, surgeons can be categorized in 3 main groups of those who usually, selectively or rarely resurface. the aim of this prospective, randomized, controlled study to is compare the isokinetic performance and clinical outcome of tkas with pr and without pr.

patients undergoing tka for primary osteoarthritis of the knee are randomly assigned to either the pr or non-pr groups. the differences between groups with respect to age, bmi, gender, and preoperative knee society score (kss), and isokinetic performance are evaluated. patients are evaluated at postoperative 3, 6, and 12 months with kss and at 6 months and 1 year with isokinetic measurements.

Eligibility criteria:
inclusion criteria: * patients aged 55 to 80 years * unilateral primary osteoarthritis exclusion criteria: * bilateral osteoarthritis * inflammatory arthritis * post-traumatic osteoarthritis * previous knee surgery * neuromuscular diseases

Keywords: patellar resurfacing isokinetic testing
is sedation necessary for transforaminal epidural injections?

Conditions: Pain, Chronic

Summary: radicular low back pain due to disc herniation is frequently observed. there are rest, medical treatments, physical medicine modalities, interventional procedures for pain and surgical options in the treatment of lumbar disc herniations. epidural interventional methods can be applied safely and effectively in patients who do not respond to conservative treatment. transforaminal epidural steroid injections (tfese) are frequently used in the interventional treatment of lumbosacral radicular low back pain. tfese is applied targetedly under fluoroscopy guidance in disc herniation. therefore, the chance of success increasestfese, which is considered a minimally invasive procedure today, is frequently preferred in interventional pain treatments. tfese can be performed with or without sedation, depending on the preference of the physician and the patient, the patient's comorbidities, the infrastructure of the hospital and the health presentation. there are conflicting and limited studies on whether sedation is necessary in interventional pain procedures.

the study will be conducted by retrospectively scanning the files of patients with paracentral/subarticular protruded disc herniation and who underwent transforaminal epidural steroid injection (tfese) to the lumbosacral region, at the algology department of kanuni sultan süleyman training and research hospital, between january 2022 and january 2024. in order to prevent heterogeneity, magnetic resonance imaging (mri) of the patients will be evaluated in consultation with a radiologist. the common consensus classification created by the american society of spine radiology (assr), american society of neuroradiology (asnr) and north american spine society (nass) is used to classify disc herniations. will be used. numeric rating scale-11 (nrs) and oswestry disability index (odi) will be recorded from the patients' files before the procedure, in the first month and in the third month to evaluate age, gender, symptom duration, pain and functionality. the initial pain severity of the patients will be determined by the nrs-11 score, and a decrease of 50% or more in the nrs-11 score in the first month after the procedure will be considered as benefiting from the treatment. the mg level of the patients before the procedure will be scanned in the hospital system and those that can be accessed will be recorded.

Eligibility criteria:
inclusion criteria: patients aged 18-65, american society of anesthesiologists (asa) 1-3, body mass index\<35 kg/m2, who underwent unilateral, single-level tfese were included.

Keywords: transforaminal epidural injections, sedation,pain
effect of a preoperative pulsed electromagnetic field and abdominal exercises on muscle strength post ventral hernioplasty

Conditions: Hernia, Ventral

Summary: the aim of this study is to investigate the impact of a preoperative pulsed electromagnetic field and abdominal exercises on muscle strength post ventral hernioplasty.

sixty patients, 25-40 years old, diagnosed with a ventral hernia and consulted for surgical hernia repair, preoperatively, were randomly assigned either into pulsed electromagnetic therapy and graduated abdominal strengthening exercises group (group a), graduated abdominal strengthening exercises group (group b), pulsed electromagnetic therapy group (group c) or group d who is instructed to presume in normal activities of daily living preoperatively, without any abdominal exercises or pemf. all treatment interventions were applied at a frequency of three sessions per week for six weeks preoperatively. abdominal muscle torque was measured by a biodex isokinetic dynamometer preoperatively at baseline and after six weeks of intervention and after four months postoperatively.

Eligibility criteria:
inclusion criteria: * being subjects of both genders. * between the age of 25-40 years. * diagnosed with a ventral hernia (grade ii \& iii) based on surgeon assessment and desired an elective surgical repair. * able to act in the abdominal training program. exclusion criteria: * patients with a strangulated hernia. * bowel obstruction, peritonitis or perforation. * urgent surgery indication. * less than one-year abdominal surgery. * infection (local or systemic). * orthopedic problem, or neurological impairment that interfere with patient ability to act in the abdominal training program. * pregnant women.

Keywords: pulsed electromagnetic field abdominal exercises ventral hernia repair
effectiveness of continuous femoral nerve block versus single shot femoral nerve block for pain control

Conditions: Post-operative Pain

Summary: both single shot femoral nerve block and continuous femoral nerve block with catheter have been shown to be effective for pain control after anterior cruciate ligament reconstruction (aclr). continuous femoral nerve block may be the more effective of the two in reducing pain scores and opioid consumption for the first 48 hours postoperatively.

the number of ambulatory procedures has steadily increased over the last decade. postoperative pain is the most common cause of delayed discharge and unexpected admission after ambulatory surgery. knee surgery was identified as one of the procedures associated with the most pain at 24 hours, with a 45% or higher incidence of moderate or severe pain. poor pain control can counteract many of the benefits of ambulatory surgery and can lead to the development of chronic pain. regional techniques have been shown to be effective after acl reconstruction, allowing faster patient recovery with fewer side-effects than intravenous administration of opioids. different regional techniques have been applied and studied after aclr. femoral nerve block for aclr either as a single bolus or as a continuous infusion markedly decreases intravenous analgesic requirements and postoperative pain. to the investigator's knowledge, no study has compared these two techniques after aclr with patellar tendon graft or allograft.

Eligibility criteria:
inclusion criteria: 1. american society of anesthesiologists score between 1-3 2. scheduled to undergo anterior cruciate ligament reconstruction with patellar tendon graft or allograft under general anesthesia exclusion criteria: 1. localized infection of the groin or generalized sepsis. 2. hypersensitivity or known allergy to local anesthetics. 3. preexisting nerve damage in surgical limb. 4. history of chronic pain with either (a) daily opioid requirement exceeding the equivalent of 50 mg morphine or (b) daily prescription of tricyclic antidepressants, gabapentin, pregabalin, or tramadol for pain. 5. patients who elect to have knee surgery under spinal anesthesia or who cannot undergo general anesthetic. 6. patients who decline to have a femoral nerve block with catheter.

Keywords: post-operative pain anterior cruciate ligament repair